Friday, December 06, 2002

I wonder if the company informed its human research subjects that chimpanzees respond to HCV differently than humans.


Nabi Biopharmaceuticals Receives Orphan Drug Designation for Civacir(TM), Investigational Hepatitis C Antibody Product in Clinical Trial

BOCA RATON, Fla., Dec 5, 2002 /PRNewswire-FirstCall via COMTEX/ -- Nabi Biopharmaceuticals (Nasdaq: NABI) announced today that the U.S. Food and Drug Administration (FDA) has granted its investigational product, Civacir(TM) [Hepatitis C Immune Globulin (Human)], Orphan Drug Designation for prevention of hepatitis C infection in liver transplant recipients. Civacir is an antibody-based therapy currently in its first clinical trial....

...Results of a previously reported study in chimpanzees showed that multiple infusions of Civacir effectively eliminated circulating HCV and protected animals against HCV-induced liver disease for as long as antibody levels were maintained.

This Civacir clinical trial is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health, and is being conducted by the NIAID Collaborative Anti-Viral Study Group at five study sites in the United States....